EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Antibody–Drug Conjugates (ADCs): A Review of Structural Design, Technological Evolution, and Future Perspectives

Guiying Wu, Zhenhai Yuan, Ming Chen, Xuan Tang, Fang Wang, Daizhou Zhang

Molecules · 02.04.2026 · 31 (7) · 1180

DOI: 10.3390/molecules31071180 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecules, online erschienen am 02.04.2026. Verfasst von Guiying Wu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Traditional Chinese Medicine, Shandong Academy of Pharmaceutical Sciences, Jinan 250101, China. Hauptthemen laut MEDLINE: Immunoconjugates, Antineoplastic Agents, Drug Design, Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 111 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: handong Province Project for Enhancing the Innovation Capacity of Sci-tech Small and Medium-sized Enterprises, Jinan Innovation Team Project, Key R&D Program of Shandong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody–drug conjugates (ADCs) have become an important class of targeted anticancer therapeutics by integrating the tumor selectivity of monoclonal antibodies with the potent cytotoxicity of small-molecule payloads through rational linker design. This review summarizes the structural fundamentals of ADCs, including antibodies, linkers, and payloads, and describes their coordinated mechanism of action. We trace the evolutionary trajectory of ADCs across three generations, highlighting key breakthroughs, limitations, and representative agents for each era. Furthermore, we elaborate on cleavage mechanisms of linkers (cleavable and non-cleavable). We also categorize and discuss cytotoxic payloads, covering traditional microtubule-disrupting agents, DNA-damaging agents, and novel mechanism-based payloads, along with their modification strategies and preclinical/clinical performance. Finally, we discuss representative and clinically influential ADC designs, with emphasis on the relationships among antibody, linker, and payload.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunoconjugatesAntineoplastic AgentsDrug DesignNeoplasmsHumansAntibodies, MonoclonalAnimals

Stichwörter der Autor:innen

antibody–drug conjugatescytotoxic payloadlinkermonoclonal antibody

Substanzen

ImmunoconjugatesAntibodies, MonoclonalAntineoplastic Agents

Autor:innen und Institutionen

  • Institute of Traditional Chinese Medicine, Shandong Academy of Pharmaceutical Sciences, Jinan 250101, China.

Förderung

  • handong Province Project for Enhancing the Innovation Capacity of Sci-tech Small and Medium-sized Enterprises
  • Jinan Innovation Team Project
  • Key R&D Program of Shandong Province

Zitieren

APA

Wu, G., Yuan, Z., Chen, M., Tang, X., Wang, F., & Zhang, D. (2026). Antibody–Drug Conjugates (ADCs): A Review of Structural Design, Technological Evolution, and Future Perspectives. Molecules, 31(7), 1180. https://doi.org/10.3390/molecules31071180

Vancouver

Wu G, Yuan Z, Chen M, Tang X, Wang F, Zhang D. Antibody–Drug Conjugates (ADCs): A Review of Structural Design, Technological Evolution, and Future Perspectives. Molecules. 2026;31(7):1180. doi:10.3390/molecules31071180

BibTeX
@article{Wu2026,
  author = {Wu, Guiying and Yuan, Zhenhai and Chen, Ming and Tang, Xuan and Wang, Fang and Zhang, Daizhou},
  title = {Antibody–Drug Conjugates (ADCs): A Review of Structural Design, Technological Evolution, and Future Perspectives},
  journal = {Molecules},
  year = {2026},
  volume = {31},
  number = {7},
  pages = {1180},
  doi = {10.3390/molecules31071180}
}
Kostenlos starten →